Mesoblast (MESO) Revenue Growth (3y) (2019 - 2023)

Mesoblast (MESO) Revenue Growth (3y) (2019 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 50.07%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 7.94%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 4.47%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 81.24%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Mesoblast 19.81 Bn 19.68 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 -30.15%
Mar 31, 2023 -2.33%
Dec 31, 2022 0.19%
Sep 30, 2022 5.83%
Jun 30, 2022 19.96%
Mar 31, 2022 24.50%
Dec 31, 2021 42.69%
Sep 30, 2021 30.29%
Jun 30, 2021 5.50%
Mar 31, 2021 25.48%
Dec 31, 2020 -27.58%
Sep 30, 2020 3.59%
Jun 30, 2020 259.21%
Dec 31, 2019 65.67%
Sep 30, 2019 73.09%
Jun 30, 2019 -58.17%